Published in Drug Week, September 9th, 2005
The company is proceeding with the evaluation of up to three new formulations, developed based on bilayer technology. This bilayer technology involves coformulation of Truvada and Sustiva as individually formulated layers combined together in one tablet. Gilead will initiate the bioequivalence studies in humans and stability studies of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.